Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to "Neutral" at Guggenheim

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) was downgraded by equities researchers at Guggenheim from a "buy" rating to a "neutral" rating in a note issued to investors on Friday, Marketbeat.com reports.

Other analysts have also issued reports about the company. William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Stifel Nicolaus cut shares of Neumora Therapeutics from a "buy" rating to a "hold" rating and lowered their price objective for the company from $6.00 to $2.00 in a research report on Friday. Bank of America reduced their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Royal Bank of Canada reissued a "sector perform" rating and issued a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Finally, HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Neumora Therapeutics presently has a consensus rating of "Hold" and an average price target of $10.14.

Neumora Therapeutics Stock Up 6.7 %

NASDAQ:NMRA traded up $0.09 on Friday, reaching $1.43. The stock had a trading volume of 1,227,622 shares, compared to its average volume of 1,422,371. The company has a market capitalization of $231.63 million, a P/E ratio of -0.76 and a beta of 2.59. Neumora Therapeutics has a 1-year low of $1.26 and a 1-year high of $18.61. The stock has a fifty day moving average price of $2.24 and a 200-day moving average price of $8.52.

Remove Ads

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. Sell-side analysts predict that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Trading of Neumora Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Windmill Hill Asset Management Ltd boosted its position in shares of Neumora Therapeutics by 299.6% in the 4th quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company's stock worth $1,106,000 after purchasing an additional 78,252 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $770,000. Wexford Capital LP boosted its holdings in Neumora Therapeutics by 15.7% during the fourth quarter. Wexford Capital LP now owns 252,122 shares of the company's stock worth $2,672,000 after buying an additional 34,243 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth about $364,000. Finally, Stempoint Capital LP bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at about $4,538,000. Institutional investors and hedge funds own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.